Related Experiment Video

Updated: Dec 27, 2025

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.2K

Structure and function of β-arrestins, their emerging role in breast cancer, and potential opportunities for

Arun K Shukla1, Hemlata Dwivedi-Agnihotri1

  • 1Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India.

Advances in Cancer Research
|February 25, 2020
PubMed

Insights

Beta-arrestins (βarrs) are key proteins in G protein-coupled receptor (GPCR) signaling. Novel functions of βarrs in breast cancer offer potential therapeutic strategies.

Area of Science:

  • Molecular Biology
  • Cellular Biology
  • Oncology

Background:

  • Beta-arrestins (βarrs) are multifunctional intracellular proteins that interact with G protein-coupled receptors (GPCRs).
  • GPCR signaling is crucial in cancer development and progression.
  • βarrs play significant roles in GPCR signaling, trafficking, and downregulation.

Purpose of the Study:

  • To provide an overview of βarr structure and function.
  • To highlight novel functional attributes of βarrs in breast cancer.
  • To discuss therapeutic strategies targeting βarrs.

Main Methods:

  • Literature review and synthesis of recent discoveries.
  • Analysis of βarr involvement in breast cancer phenotypes.
  • Exploration of methods to modulate βarr function.

Main Results:

  • βarrs exhibit diverse functions beyond canonical GPCR signaling.
  • Specific βarr roles in breast cancer progression and metastasis are being uncovered.
  • Modulating βarr activity presents potential therapeutic avenues.

Conclusions:

  • βarrs are critical regulators of GPCR signaling with implications in cancer.
  • Emerging research reveals novel βarr functions in breast cancer.
  • Targeting βarrs holds promise for future cancer therapies.
Keywords:
Allosteric modulatorsBiased agonismBreast cancerCellular signalingEndocytosisGPCRsProtein-protein interactionβ-Arrestins

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.6K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K